Soligenix (SNGX)
(Delayed Data from NSDQ)
$3.87 USD
+0.05 (1.26%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $3.88 +0.01 (0.31%) 4:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Soligenix Inc. [SNGX]
Reports for Purchase
Showing records 21 - 40 ( 98 total )
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Data Read-Outs Approaching in Two Pivotal Trials
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Lighting up the Future for Cutaneous T-Cell Lymphoma Patients
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to better allocate resources within our coverage universe.
Provider: H.C. Wainwright & Co., Inc.
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
2017 Results Looking Toward Enrollment Events.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
Pressing the Pause Button as Timelines Continue to Slip; Downgrade to Neutral; Target Reduced to $2.70
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Soligenix Inc.
Industry: Medical - Biomedical and Genetics
3Q17 Results; SGX301 Readout Expected in 2H18 as Lead Value Driver; Target Reduced to $5.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J